Get the Stockscreener App
1.55
0.65%
0.01
After Hours:
1.55
Rein Therapeutics Inc stock is traded at $1.55, with a volume of 1.01M.
It is up +0.65% in the last 24 hours and up +6.90% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.54
Open:
$1.53
24h Volume:
1.01M
Relative Volume:
1.08
Market Cap:
$40.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+13.97%
1M Performance:
+6.90%
6M Performance:
-21.32%
1Y Performance:
+0.00%
1-Day Range:
$1.47
$1.56
1-Week Range:
$1.35
$1.56
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.55 | 40.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
White House AI Czar Defends Trump Push to Rein In State Rules - Yahoo Finance
Rein Therapeutics ends agreements with Yorkville, incurs no penalties By Investing.com - Investing.com Nigeria
Rein Therapeutics ends agreements with Yorkville, incurs no penalties - Investing.com India
Rein Therapeutics Ends Key Financial Agreements - TipRanks
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Rein Therapeutics Inc. stock attractive for long term wealth building2025 Winners & Losers & Comprehensive Market Scan Insights - Newser
Is Rein Therapeutics Inc. stock positioned well for digital economyAnalyst Upgrade & Low Drawdown Investment Strategies - Newser
Hedge Fund Bets: Can Rein Therapeutics Inc stock attract ESG capital inflowsJuly 2025 Price Swings & Daily Price Action Insights - BỘ NỘI VỤ
Bank Julius Baer & Co. Ltd Zurich Decreases Stock Position in Expedia Group, Inc. $EXPE - Defense World
Bank Julius Baer & Co. Ltd Zurich Sells 8,729 Shares of General Motors Company $GM - Defense World
Will Rein Therapeutics Inc. stock gain from strong economy - newser.com
Will Rein Therapeutics Inc. stock outperform Nasdaq indexMarket Movement Recap & Expert Curated Trade Setup Alerts - newser.com
Will Rein Therapeutics Inc. stock continue upward momentumJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
What drives Rein Therapeutics Inc stock priceVWAP Trading Strategies & Exceptional Growth Portfolio - earlytimes.in
Why retail investors favor Rein Therapeutics Inc. stockPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Omdia: Middle East Smartphone Market up 23% in 3Q25; Supply Issues to Rein in 2026 Growth to 1% - Yahoo Finance
Voss capital reports $127k Rein Therapeutics (NASDAQ:RNTX) purchase By Investing.com - Investing.com South Africa
How Rein Therapeutics Inc. stock reacts to bond yieldsWeekly Risk Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Will Rein Therapeutics Inc. stock maintain momentum in 2025Weekly Investment Recap & Expert Curated Trade Ideas - newser.com
Voss capital reports $127k Rein Therapeutics (NASDAQ:RNTX) purchase - Investing.com
Owner Voss Capital LP Buys 104,183 ($127.6K) Of Rein Therapeutics Inc [RNTX] - TradingView
Ranking Rein Therapeutics Inc. among high performing stocks via tools - newser.com
Comparing Rein Therapeutics Inc. in custom built stock radars2025 Bull vs Bear & Daily Oversold Bounce Ideas - newser.com
Price momentum metrics for Rein Therapeutics Inc. explained2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):